LightNews — News, ranked by scholars

Kathryn Mary Crowley

@kathrynmarycrowley.bsky.social

Living with MASLD? If you are based in any of Ireland's northern counties, please get in touch via my website (should you wish to share some of your story). My piece will address stigma and inform readers. #MASLD #Belfast #journorequest #liverhealth @liveruk.bsky.social #pathsky #liversky

Cartoon of a liver with an umbrella over it. Text reads 'Global Think-tank on Steatotic Liver Disease.' The sticker was shared at the World Health Summit 2026 following sessions on liver disease.

October 29, 2026 at 3:43 PM

Raju Kumar

@tumorscholar.bsky.social

Furan fatty acids reprogram hepatic lipid metabolism via acyl-CoA conjugates in obesity.

#LiverResearch #LiverSky #Hepatology
https://doi.org/10.1126/sciadv.aeg5357

Furan fatty acids reprogram hepatic lipid metabolism via acyl-CoA conjugates in obesity.

Dietary fish oil (FO) and omega-3 fatty acids are associated with cardiometabolic benefits, yet their molecular mediators remain incompletely defined. Furan fatty acids (FuFAs), a distinct lipid class enriched in FO, have emerged as potential regulators of metabolic health. Here, we identify and qua

doi.org

October 29, 2026 at 2:28 PM

Raju Kumar

@tumorscholar.bsky.social

IL-19 limits macrophage-driven inflammation in acetaminophen-induced liver injury

#LiverResearch #LiverSky #Hepatology
https://doi.org/https://www.sciencedirect.com/science/article/pii/S0168827826027431?dgcid=rss_sd_all

IL-19 limits macrophage-driven inflammation in acetaminophen-induced liver injury

Publication date: November 2026 Source: Journal of Hepatology, Volume 85, Issue 5 Author(s): Dongwei Jia, Yasuko Iwakiri

doi.org

October 26, 2026 at 10:20 AM

Raju Kumar

@tumorscholar.bsky.social

Non-invasive tests in metabolic dysfunction-associated steatotic liver disease: the LITMUS prospective multicentre diagnostic accuracy study.

#MASLD #LiverTherapy #LiverSky #Hepatology
https://doi.org/10.1016/s0140-6736(26)01145-1

Non-invasive tests in metabolic dysfunction-associated steatotic liver disease: the LITMUS prospective multicentre diagnostic accuracy study.

The advent of regulatory-approved pharmacological treatments for metabolic dysfunction-associated steatotic liver disease (MASLD) calls for precise, non-invasive biomarkers that facilitate early diagnosis, support therapy selection, and aid clinical trial enrolment. The European multicentre LITMUS s

doi.org

November 1, 2026 at 12:47 PM

Raju Kumar

@tumorscholar.bsky.social

Prediabetes and diabetes as drivers of fibrosis in MASLD: roles of obesity, adipose tissue dysfunction and insulin resistance

#MASLD #LiverFibrosis #LiverSky #Hepatology
https://doi.org/10.1007/s00125-026-06904-1

Prediabetes and diabetes as drivers of fibrosis in MASLD: roles of obesity, adipose tissue dysfunction and insulin resistance

Aims/hypothesis Methods Results Conclusions/interpretation Graphical Abstract

doi.org

October 26, 2026 at 10:20 AM

Raju Kumar

@tumorscholar.bsky.social

Targeted lactate depletion via gluconeogenesis by engineered hepatocyte-based micronanorobots for radiosensitization and immune activation

#LiverResearch #LiverSky #Hepatology
https://doi.org/10.1016/j.xcrm.2026.103123

Targeted lactate depletion via gluconeogenesis by engineered hepatocyte-based micronanorobots for radiosensitization and immune activation

Fan et al. develop CXCR4-engineered hepatocyte cytoplasts integrated with Au-Pt nanorobots to deplete tumor lactate through gluconeogenesis. Lactate depletion suppresses repair-associated lactylation and impairs MRN-mediated DNA repair, while Au-Pt catalysis amplifies radiation-induced damage. This

doi.org

October 26, 2026 at 10:20 AM

Philippa Matthews

@pippa-matt.bsky.social

The #HBV field advances…
First steps on the road to functional #cure. 20% surface antigen loss in selected individuals… this is modest overall but proof of principle that cure is possible, & life changing for those in whom it works
🧪 @fda.gov #MedSky #LiverSky #Hepatitis
us.gsk.com/en-us/media/...

Hibsago (bepirovirsen) approved in the US for the treatment of chronic hepatitis B (CHB) | GSK US

Approval based on phase III data showing unprecedented functional cure rates compared to standard of care.

us.gsk.com

October 21, 2026 at 5:03 AM

Raju Kumar

@tumorscholar.bsky.social

Glutamine metabolism keeps pathogenic hepatic CD4 + T cells in check.

#MASLD #LiverResearch #LiverSky #Hepatology
https://doi.org/10.1016/j.cmet.2026.09.004

Glutamine metabolism keeps pathogenic hepatic CD4 + T cells in check.

Sawada et al. show that glutamine metabolism through glutaminolysis restrains O-GlcNAcylation and pathogenic inflammatory cytokine production by hepatic CD4 + T cells during MASLD. Glutamine supplementation restores hepatic glutamine availability and limits liver injury, and these findings reveal a

doi.org

October 19, 2026 at 2:40 PM

Philippa Matthews

@pippa-matt.bsky.social

Raising funds for @liveruk.bsky.social in honour and memory of @ahmedelsharkawy.bsky.social.
Ahmed was a wonderful human being and clinician, tirelessly providing the best care for his patients, alongside advocating for people living with #LiverDisease.
💔 #MedSky #LiverSky 🧪
gofund.me/eb371f9a8

Donate to Ahmed Elsharkawy, organized by Philippa Olubodun

In memory of Ahmed, a very special doctor, colleague, collaborator, advocate and friend, let’s ra… Philippa Olubodun needs your support for Ahmed Elsharkawy

gofund.me

October 17, 2026 at 12:00 PM

Raju Kumar

@tumorscholar.bsky.social

A multicohort proteomics-based machine learning score (MASHPredict) for noninvasive diagnosis and long-term prognostication of metabolic dysfunction-associated steatohepatitis

#MASH #LiverFibrosis #LiverSky #Hepatology
https://doi.org/10.3389/fimmu.2026.1849699

A multicohort proteomics-based machine learning score (MASHPredict) for noninvasive diagnosis and long-term prognostication of metabolic dysfunction-associated steatohepatitis

BackgroundMetabolic dysfunction-associated steatohepatitis (MASH) can progress to cirrhosis and hepatocellular carcinoma, yet the invasiveness of liver biopsy limits its clinical utility. Accurate noninvasive diagnostic tools are essential for improved patient risk stratification.MethodsA machine le

doi.org

October 16, 2026 at 9:57 AM

Hans Popper Hepatopathology Society

@liverpath-hphs.bsky.social

⏰One day left to register for the HPHS Annual Retreat, December 5-6, in Atlanta!
Registration and case/discussion submission portals close October 16, 2026 @ 11:59 EDT.
#liverpath #liversky

Hans Popper Hepatopathology Society @liverpath-hphs.bsky.social · Oct 2

Register for our Annual Retreat now! hanspopperhepatopathologysociety.org/annual-retre...
📅December 5-6
🌎Emory Conference Center, Atlanta, GA
🎓A little case told me... & The sounding board (submissions open), discussion panels (SLD, IHC of tumours)
🪩Social and dinner
#pathsky #liverpath

Annual Retreat – Registration LIVE – Hans Popper Hepatopathology Society

hanspopperhepatopathologysociety.org

October 15, 2026 at 7:37 PM

Raju Kumar

@tumorscholar.bsky.social

Inhibiting fructose metabolism to treat fatty liver

#LiverResearch #LiverSky #Hepatology
https://doi.org/10.1038/s42255-026-01627-4

Inhibiting fructose metabolism to treat fatty liver

doi.org

October 13, 2026 at 12:17 PM

The Lancet Gastroenterology & Hepatology

@lancetgastrohep.bsky.social

Our November 2026 issue is out now - visit www.thelancet.com/gastrohep!

Content includes: #IBD, #MASH, #livercancer, #colorectalcancer, #cirrhosis, #IBS + more...

#GastroSky #MedSky #LiverSky #IBDSky #OncSky

October 8, 2026 at 8:57 AM

Hans Popper Hepatopathology Society

@liverpath-hphs.bsky.social

Are you at #IAP2026? 🌸 So are we!
💬What to do with difficult well-differentiated hepatocellular lesions
Speakers: Drs Luca Di Tommaso, Michael Torbenson, Rondell Graham, & Xuchen Zhang
📆October 9, 19:00-21:00
📍Room 3

#liverpath #liversky #pathsky

October 8, 2026 at 1:26 PM

Raju Kumar

@tumorscholar.bsky.social

Ulcerative colitis remission leaves persistent LCN2+ macrophages with heightened glycolysis and H3K9la memory.

#MASLD #GutLiverAxis #LiverSky #Hepatology
https://doi.org/10.1016/j.cmet.2026.09.008

Histone lactylation scarring transmits metabolic and epigenetic memory across the gut-liver axis

Dong et al. show that ulcerative colitis remission leaves persistent LCN2+ macrophages with heightened glycolysis and H3K9la memory. Upon high-fat diet challenge, these cells contribute to gut-to-liver inflammatory transmission and increased susceptibility to steatotic liver disease through a chroma

doi.org

October 8, 2026 at 8:28 AM

Raju Kumar

@tumorscholar.bsky.social

KCs as the primary hepatic reservoir for MNPs in young male mice.

#LiverImmunology #LiverSky #Hepatology
https://doi.org/10.1038/s42255-026-01615-8

Size-dependent plastic exposure disrupts macrophage function and tissue-specific metabolism.

Plastic pollution is an emerging yet understudied environmental risk to the immune system. Once ingested, microplastic and nanoplastic particles (MNPs) can translocate from the gut to internal organs 1-3 , with macrophages serving as primary targets 4 . Kupffer cells (KCs), the liver-resident macrop

doi.org

October 5, 2026 at 9:42 AM

Raju Kumar

@tumorscholar.bsky.social

Macrophage-derived IL-27 sustains autoreactive CD8+ cytotoxic T cells in autoimmune hepatitis

#LiverSky #Hepatology
https://doi.org/10.64898/2026.09.25.754422

Macrophage-derived IL-27 sustains autoreactive CD8+ cytotoxic T cells in autoimmune hepatitis

Chronic or persistent T cell activation is widely thought to culminate in T cell exhaustion, yet how autoreactive CD8+ T cells remain functionally intact despite sustained self-antigen exposure is poorly understood. In chronic infection and cancer this durability is attributed to stem-like, TCF1+ PD

doi.org

October 1, 2026 at 10:16 AM

The Lancet Gastroenterology & Hepatology

@lancetgastrohep.bsky.social

New research - Short-course prophylaxis with the Toronto HCV protocol for recipients of non-liver solid organ transplants from donors with hepatitis C viraemia: a retrospective, matched cohort study

www.thelancet.com/journals/lan...

#LiverSky #TransplantSky #HepSky

Short-course prophylaxis with the Toronto HCV protocol for recipients of non-liver solid organ transplants from donors with hepatitis C viraemia: a retrospective, matched cohort study

The Toronto HCV protocol prevented or rapidly cleared HCV infection in D+R– recipients of non-liver solid organ transplants, with no difference in overall survival versus matched D−R− controls. This s...

www.thelancet.com

September 30, 2026 at 9:04 AM

Springer Medicine

@springermedicine.com

NIT-based strategies that accurately identify ‘at-risk’ #MASH are needed to guide patient selection for drug therapy and assess treatment response.

Explore available NITs and emerging ones that consider mechanisms beyond fibrosis.

👉️ buff.ly/RBnRBdu

#LiverSky

Non-invasive Assessment and Therapeutic Targeting in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Overcoming the Dissonance Between Drug Development and Precision Medicine

NIT-based strategies that accurately identify ‘at-risk’ MASH are needed to guide patient selection for drug therapy and assess treatment response. Explore available NITs and emerging ones that…

www.springermedicine.com

September 30, 2026 at 10:54 AM

Hans Popper Hepatopathology Society

@liverpath-hphs.bsky.social

This Friday! HPHS Western Regional Session webinar:
💊DILI in the era of oncologic immunomodulators
⏱️October 2, 12 PM EDT
🌐 Zoom
🎙️Drs David Kleiner, Lily Dara, and Kwun Wen
Check your e-mail for free registration info
mailchi.mp/0250206de480...
#liverpath #liversky #pathsky

This Friday: DILI in the era of oncologic immunomodulators

mailchi.mp

September 29, 2026 at 2:11 PM

Raju Kumar

@tumorscholar.bsky.social

Single-nucleus transcriptomics refine the hepatic cellular context of the MASLD proteosurvival signature.

#MASLD #LiverResearch #LiverSky #Hepatology
https://doi.org/10.1136/gutjnl-2026-340378

Single-nucleus transcriptomics refine the hepatic cellular context of the MASLD proteosurvival signature.

doi.org

September 28, 2026 at 11:08 AM

Raju Kumar

@tumorscholar.bsky.social

B-cells on the rise: Serum IgA Identifies a High-Risk Biological Phenotype in MASLD

#MASLD #LiverSky #Hepatology
https://doi.org/https://www.sciencedirect.com/science/article/pii/S0168827826028990?dgcid=rss_sd_all

B-cells on the rise: Serum IgA Identifies a High-Risk Biological Phenotype in MASLD

Publication date: Available online 25 September 2026 Source: Journal of Hepatology Author(s): Mathias Heikenwalder, Yasuko Iwakiri

doi.org

September 28, 2026 at 11:08 AM

Springer Medicine

@springermedicine.com

#MedNews - An international panel of experts has proposed a framework for the use of resmetirom and semaglutide in the treatment of patients with #MASH and significant fibrosis but no cirrhosis.

Full story 👉️ buff.ly/lD8hqCm

#LiverSky